Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
The Naval Information Warfare Center Pacific is soliciting proposals for the development and fielding of intelligence, surveillance and reconnaissance systems…
The Department of War is accelerating its push into unmanned systems, moving beyond experimentation toward large-scale production, streamlined acquisition and…
BAE Systems has received a $117.7 million contract modification from the U.S. Navy to support depot-level modernization, maintenance and repair of USS…
Advanced wireless infrastructure is becoming as strategically important as artificial intelligence in modern defense operations 5G standalone enables network slicing,…
